Continuing Education Activity

Dexrazoxane is a medication used in the management and treatment of anthracycline-induced cardiotoxicity and extravasation injuries. It is in the class of medications known as cardioprotectants. This activity reviews the indications, action, and contraindications for dexrazoxane as a valuable agent in the management of cardiotoxicity and anthracycline extravasation leading to tissue damage. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the care of patients with anthracycline-induced cardiotoxicity, extravasation injuries and related conditions.

Objectives:

• Describe the mechanism of action of dexrazoxane.
• Review the administration of dexrazoxane including dosage adjustments in renal and hepatic impaired patients.
• Identify the adverse effects seen with dexrazoxane use along with the protocols in place as regards to the toxicity of this drug.
• Outline the importance of collaboration and coordination among the interprofessional team to enhance care delivery for patients receiving dexrazoxane.

Indications

Dexrazoxane, an FDA-approved cardioprotective drug, has been successfully used to ameliorate cardiac toxicity seen in anthracycline-based (e.g., doxorubicin, daunorubicin, epirubicin) chemotherapy recipients for cancer, mainly in advanced breast cancer patients, adult patients with soft tissue sarcomas, or small-cell lung cancer.[1][2] It is used intravenously in conjunction with the anthracycline of choice to decrease the incidence of cardiomyopathy and congestive heart failure.[3] 

Dexrazoxane has also shown an indication in the prevention of surrounding tissue damage caused by extravasation of anthracyclines, which can occur upon administration of these chemotherapeutic drugs.[4]

However, dexrazoxane treatment does not completely eliminate the risk of cardiac toxicity induced by anthracyclines, so it is necessary to check on the patient’s cardiac function before and consistently during therapy to analyze the left ventricular ejection fraction (LVEF).

FDA-approved indications:

1. Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use.

2. Dexrazoxane can also be used to treat tissue damage caused by anthracyclines when they leak from the vein while being administered.

Non-FDA-approved indication:

Although a study is still underway as of this writing, dexrazoxane may act as a beneficial neuroprotectant to treat neurodegeneration in patients with Parkinson's disease.[5]

Mechanism of Action

Anthracyclines are known to potentiate cytotoxic effects via different mechanisms, which include intercalating into nuclear DNA, the creation of reactive oxygen species, and inducing apoptosis or cell death.

Dexrazoxane appears to ameliorate the cardiotoxicity seen with anthracyclines by fusing with free and bound iron, thereby decreasing the formation of anthracycline-iron complexes and, eventually, the production of reactive oxygen species, which are harmful to the surrounding cardiac tissue.[1] 

Dexrazoxane is known to be from the family of compounds known as bisdioxopiperazine. Unlike its iron-chelating analog ethylenediaminetetraacetic acid (EDTA), dexrazoxane is ring-enclosed and hydrophilic. However, unlike EDTA, it diffuses into cells readily. Upon its chemical breakdown, dexrazoxane transforms into a form similar to EDTA, a potent iron chelator; this, consequently, displaces excess iron from the anthracycline thought to be liable, in part, for the cardiomyopathy seen with anthracyclines.[6]

Dexrazoxane also acts as a DNA topoisomerase II inhibitor, which happens to be the same target of the DNA topoisomerase II anti-cancer agent (e.g., the anthracyclines), antagonizing the formation of the topoisomerase II cleavage complex and also rapidly degrading topoisomerase II beta.[7]

Dexrazoxane, however, does not induce harmful breaks in the double-strands of DNA as the anthracyclines.[8] 

Dexrazoxane was also found to enhance the viability of cells and impose cardiac function protection by attenuating the apoptosis of cardiomyocytes and necroptosis simultaneously after treatment with doxorubicin via interference of the p38MAPK/NF-κB pathways.[9]

Administration

The drug's administration is usually via intravenous infusion over 15 minutes. It is not recommended as a push.

The suggested dosage ratio of dexrazoxane to doxorubicin is 10 to 1 (eg, 500 mg/m² dexrazoxane to 50 mg/m² doxorubicin). It is advisable to give dexrazoxane before doxorubicin. Administration of doxorubicin within half an hour after the completion of dexrazoxane infusion is recommended.

Administer the diluted solution of dexrazoxane in lactated Ringer's solution intravenously over a quarter of an hour (15 minutes) before doxorubicin. Doxorubicin is usually infused approximately 30 minutes after dexrazoxane. It is not advisable to use dexrazoxane with a non-anthracycline chemotherapy regimen.

For extravasation treatment, the proposed dosage and rate is 1,000 mg/m² IV within 6 hours post extravasation given over 1 to 2 hours in a different large vein. This administration is then followed with doses of 1,000 mg/m² and 500 mg/m² after 2 and 3 days, respectively.

The dosing mechanism differs in people with renal or hepatic impairment. 

Dosing in Renal Impaired Patients

The dose of dexrazoxane requires a reduction in patients who have moderate to significant renal impairment (eg, creatinine clearance lower than 40 mL/min) by 50%, i.e., dexrazoxane to doxorubicin ratio reduced to 5 to 1 (eg, 200 mg/m² dexrazoxane: 40 mg/m² doxorubicin).

Dosing in Hepatic Impairment

In a patient with hyperbilirubinemia, it is necessary to decrease the dosage of doxorubicin, leading to a subsequent dosage reduction of dexrazoxane in this group of patients while still maintaining the 10 to 1 ratio.

Dexrazoxane is recommended for use only in patients who have been administered an increasing doxorubicin dose of 300 mg/m² or doses of epirubicin >550 mg/m² and are continuing with anthracycline therapy.[10]

Adverse Effects

The common side effects that culminate from dexrazoxane use include dose-limiting myelotoxicity (neutropenia, leukopenia, granulocytopenia, and thrombocytopenia), which is very similar to the side-effect profile of anthracyclines. It is, therefore, challenging to distinguish the adverse effects seen with dexrazoxane use from those of anthracycline chemotherapy. Other adverse effects include nausea/vomiting, increased renal excretion of iron and zinc, hair loss, mucositis, inconsistent increases in liver enzymes (alanine aminotransferase/aspartate aminotransferase), reactions at the injection site such as pain, superficial phlebitis, which led to the recommendation that dexrazoxane should be administered via a large vein.[4][11][12] Embryo-fetal toxicity and male infertility were also noted in studies conducted on mice.

Recently, there have been concerns about the risk, particularly in pediatric patients, with long-term effects of dexrazoxane, who continuously received doses to inhibit cardiotoxicity. Although very sporadic, the incidence of other primary malignancies (myelodysplastic syndrome and acute myeloid leukemia) in the patient group treated with dexrazoxane manifested a threefold increase compared with controls, which researchers documented in two randomized studies.[13][14]

Contraindications

According to the FDA, dexrazoxane classifies as a Category D drug.

In a study conducted on pregnant mice and rabbits, dexrazoxane dispensation led to toxicities in embryos and their mothers, as well as embryonal malformation at doses notably lower than those clinically approved for human use.

Dexrazoxane use could also lead to infertility in males based on its effects on a repeated dose toxicology research. During this study, rats and dogs received the drug every week for six weeks, in doses that were significantly lower than the specified human dose, with the dogs receiving doses equal to those given to humans. These led to notable cases of testicular atrophy in these test subjects, subsequently attributed to dexrazoxane use.

Monitoring

There are no current guidelines in place for monitoring dexrazoxane. However, this drug leads to an acute rise in liver protein production, which may be indicated by increased liver function tests (LFT), i.e., elevated alkaline phosphatase and aspartate aminotransferase. Constant monitoring of liver enzymes may be required with the administration of dexrazoxane, keeping in mind that a combination of both dexrazoxane and doxorubicin would lead to a greater increase in hepatic protein production than dexrazoxane alone.[15]

Toxicity

There is no data on toxicity in the trials of dexrazoxane, and no known antidote for a reversal exists in the literature.

In cases of a suspected overdose, management using good supportive care is advisable. These interventions include targeting areas such as infection treatment and control and fluid management, with regular preservation of nutritional requirements.

Enhancing Healthcare Team Outcomes

Dexrazoxane is approved clinically for anthracycline-induced cardiotoxicity (reducing the incidence of congestive heart failure and LVEF dysfunction) and extravasation. This drug is only recommended for use intravenously. Healthcare providers comprising of physicians (ranging from the patient's primary care provider to the oncologist as well a psychologist to deal with any form of mental illness the patient could be going through), nurses, and pharmacists, need to be cognizant of the most common side effects of this drug which is myelosuppression and work together to assess dosage of this drug, adjusting doses if and when necessary to combat adverse consequences seen with myelosuppression, monitor hematological function, and tackle any early signs of infection or bleeding. It is also critical to note that dexrazoxane does not completely improve cardiac dysfunction associated with the use of anthracyclines; hence, constant monitoring of heart function should be advised.

It is also important to get a cardio-oncologist specialist involved when heart failure or a significant decline of left ventricular ejection fraction (LVEF) occurs during chemotherapy. This assistance is critical for careful decision-making regarding further exposure to cardiotoxic cancer treatment.

Oncology nurses will be administering this drug in most cases and need to be conversant with the adverse effects, which could mimic those seen with anthracyclines, reporting any issues to the physician team as well as assessing the patient's vitals and injection sites for any signs of inflammation. Patients should be made aware of the adverse reaction seen with dexrazoxane and advised to report any changes noted as soon as possible. 

Their obstetrician should also counsel patients on pregnancy planning and prevention, as this medication is a known teratogen and can cause fetal harm. Female patients should use effective contraception during treatment.

It is unknown if dexrazoxane is secreted in breast milk and has any effect on milk production or the breastfed infant. Due to the unknown nature of this drug on milk production or secretion, women should halt breastfeeding while on dexrazoxane therapy and for two weeks after the last dose.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs. 1998 Sep;56(3):385-403. [PubMed: 9777314]

2.

Cvetković RS, Scott LJ. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65(7):1005-24. [PubMed: 15892593]

3.

Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. [PubMed: 16781284]

4.

Langer SW. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res. 2014;6:357-63. [PMC free article: PMC4168851] [PubMed: 25246808]

5.

Mei M, Zhou Y, Liu M, Zhao F, Wang C, Ding J, Lu M, Hu G. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 01;160:107758. [PubMed: 31494143]

6.

Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol. 1995 Sep 28;50(7):953-8. [PubMed: 7575679]

7.

Cruz M, Duarte-Rodrigues J, Campelo M. Cardiotoxicity in anthracycline therapy: Prevention strategies. Rev Port Cardiol. 2016 Jun;35(6):359-71. [PubMed: 27255173]

8.

Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009 May;9(5):338-50. [PMC free article: PMC2748742] [PubMed: 19377506]

9.

Yu X, Ruan Y, Huang X, Dou L, Lan M, Cui J, Chen B, Gong H, Wang Q, Yan M, Sun S, Qiu Q, Zhang X, Man Y, Tang W, Li J, Shen T. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem Biophys Res Commun. 2020 Feb 26;523(1):140-146. [PubMed: 31837803]

10.

Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V., Dexrazoxane Study Group. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006 Apr;17(4):614-22. [PubMed: 16423847]

11.

Vogel CL, Gorowski E, Davila E, Eisenberger M, Kosinski J, Agarwal RP, Savaraj N. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest New Drugs. 1987;5(2):187-98. [PubMed: 3115912]

12.

Holcenberg JS, Tutsch KD, Earhart RH, Ungerleider RS, Kamen BA, Pratt CB, Gribble TJ, Glaubiger DL. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep. 1986 Jun;70(6):703-9. [PubMed: 3089595]

13.

Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia. 2010 Feb;24(2):355-70. [PMC free article: PMC4300959] [PubMed: 20016527]

14.

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007 Feb 10;25(5):493-500. [PubMed: 17290056]

15.

Zima T, Tesar V, Sherwood R, Sood A, Au LC, Richardson PJ, Preedy VR. Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo. Toxicol Pathol. 2001 Nov-Dec;29(6):591-9. [PubMed: 11794374]

Disclosure: Chiamaka Eneh declares no relevant financial relationships with ineligible companies.

Disclosure: Manidhar Reddy Lekkala declares no relevant financial relationships with ineligible companies.